Platinum chemotherapeutic agents such as cisplatin are currently used in the treatment of
various malignancies such as lung cancer. However, their efficacy is significantly hindered …

The purpose of the present review was to determine whether the use of postoperative
adjuvant systemic therapy in patients with completely resected non–small-cell lung cancer …

Numerous studies have been published on single aspects of pulmonary adenocarcinoma
(ADC). To comprehensively link clinically relevant ADC characteristics, we evaluated …

Introduction Tumor protein p53 gene (TP53) mutations are common in stage I through III non–
small cell lung cancer, but clinical trials have shown inconsistent results regarding their …

The quest for markers of sensitivity to cytotoxic agents has been ongoing for decades. In non–
small-cell lung cancer, platinum compounds represent the cornerstone of systemic therapy …

Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung
cancer (NSCLC) despite poor response rates and limited response duration. It has been …

Tobacco smoking is a common risk factor for lung cancer and head and neck cancer.
Molecular changes such as deregulation of miRNA expression have been linked to tobacco …

Purpose Retrospective studies indicate that expression of excision repair cross
complementing group 1 (ERCC1) protein is associated with platinum resistance and survival …

Purpose Drug resistance is not only one of the major obstacles to treatment but also a poor
prognosis in advanced non-small cell lung cancer (NSCLC) patients. The aim of this study …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in Western
countries. Despite novel molecular therapies, the majority of patients with advanced or …